| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Capricor Therapeutics, Inc. have bought $0 and sold $0 worth of Capricor Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Capricor Therapeutics, Inc. have bought $5.02M and sold $474.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,798,507 shares for transaction amount of $15M was made by Nippon Shinyaku Co Ltd (10 percent owner) on 2024‑09‑20.
| 2024-09-20 | Nippon Shinyaku Co Ltd | 10 percent owner | 2.8M 9.1284% | $5.36 | $15M | +152.28% | ||
| 2023-10-12 | Musket David B | director | 410 0.0015% | $2.75 | $1,128 | +63.96% | ||
| 2023-10-10 | COLLIER EARL M JR | director | 10,000 0.0395% | $2.83 | $28,300 | +62.63% | ||
| 2023-10-09 | Musket David B | director | 5,083 0.02% | $2.82 | $14,334 | +66.01% | ||
| 2023-10-06 | Auwaerter Paul Gisbert | director | 5,000 0.019% | $2.84 | $14,200 | +58.45% | ||
| 2023-10-04 | Musket David B | director | 2,500 0.0095% | $2.90 | $7,250 | +61.62% | ||
| 2023-04-17 | Sale | Avat Xavier | 14,772 – | $64,258.00 | $949.22M | +3.61% | ||
| 2023-03-28 | Sale | Avat Xavier | 3,000 0.0118% | $4.06 | $12,180 | +6.46% | ||
| 2022-06-29 | Sale | Musket David B | 28,215 0.1163% | $3.77 | $106,371 | +19.68% | ||
| 2022-06-29 | Avat Xavier | CHIEF BUSINESS OFFICER | 1,500 0.0062% | $3.76 | $5,643 | +19.68% | ||
| 2022-06-27 | Sale | Musket David B | 17,775 0.0736% | $4.44 | $78,921 | +1.59% | ||
| 2017-05-09 | CEDARS SINAI MEDICAL CENTER | 10 percent owner | 2.29M 11.0606% | $3.10 | $7.1M | -46.21% | ||
| 2017-05-09 | Manzo Louis | director | 20,000 0.0966% | $3.10 | $62,000 | -46.21% | ||
| 2017-05-09 | Musket David B | director | 50,000 0.2415% | $3.10 | $155,000 | -46.21% | ||
| 2016-09-21 | CEDARS SINAI MEDICAL CENTER | 10 percent owner | 625,000 3.0673% | $3.20 | $2M | -26.89% | ||
| 2016-03-16 | CEDARS SINAI MEDICAL CENTER | 10 percent owner | 833,332 4.8375% | $2.40 | $2M | +29.40% | ||
| 2016-03-16 | GRASMICK LOUIS J | director | 182,738 1.0608% | $2.40 | $438,571 | +29.40% | ||
| 2016-03-16 | St. John Edward A. | 10 percent owner | 833,332 4.8375% | $2.40 | $2M | +29.40% | ||
| 2016-03-16 | Marban Linda | Chief Executive Officer | 30,456 0.1768% | $2.40 | $73,094 | +29.40% | ||
| 2016-03-16 | Manzo Louis | director | 200,000 1.161% | $2.40 | $480,000 | +29.40% |
| Nippon Shinyaku Co Ltd | 10 percent owner | 7090351 15.5092% | $172.65M | 1 | 0 | +152.28% |
| CEDARS SINAI MEDICAL CENTER | 10 percent owner | 4049959 8.8587% | $98.62M | 4 | 0 | +25.52% |
| Marban Eduardo | 10 percent owner | 3173354 6.9413% | $77.27M | 2 | 0 | <0.0001% |
| KASH PETER M | director | 1596208 3.4915% | $38.87M | 3 | 0 | |
| TANEN DAVID M | director | 1520705 3.3263% | $37.03M | 4 | 0 | |
| GRASMICK LOUIS J | director | 1059740 2.318% | $25.8M | 4 | 0 | +8.61% |
| St. John Edward A. | 10 percent owner | 842439 1.8427% | $20.51M | 2 | 0 | +25.52% |
| Marban Linda | Chief Executive Officer | 273709 0.5987% | $6.66M | 3 | 0 | +1.25% |
| Manzo Louis | director | 138384 0.3027% | $3.37M | 3 | 0 | +25.52% |
| BREWER RICHARD B | Executive Chairman | 125000 0.2734% | $3.04M | 1 | 0 | |
| Kazam Joshua A | director | 38084 0.0833% | $927,345.40 | 9 | 0 | +21.63% |
| Musket David B | director | 31536 0.069% | $767,901.60 | 5 | 2 | +53.3% |
| COLLIER EARL M JR | director | 26856 0.0587% | $653,943.60 | 1 | 0 | +62.63% |
| Evans Daron | Chief Financial Officer | 25652 0.0561% | $624,626.20 | 7 | 0 | |
| Lieu Hsiao | Executive VP, Clinical Dev. | 12600 0.0276% | $306,810.00 | 2 | 0 | |
| Krasney Karen | EVP, General Counsel | 11156 0.0244% | $271,648.60 | 2 | 0 | +25.52% |
| Strumph Peter M | Chief Executive Officer | 7580 0.0166% | $184,573.00 | 3 | 0 | |
| Auwaerter Paul Gisbert | director | 5000 0.0109% | $121,750.00 | 1 | 0 | +58.45% |
| GERSHELL LELAND | CHIEF FINANCIAL OFFICER | 2100 0.0046% | $51,135.00 | 1 | 0 | +29.4% |
| Bergmann Anthony | Vice President of Finance | 2030 0.0044% | $49,430.50 | 1 | 0 | +29.4% |
| SCHAFER GREGORY W | director | 100 0.0002% | $2,435.00 | 1 | 0 | |
| Avat Xavier | 0 0% | $0 | 1 | 1 | +19.68% |
$14,874,415 | 78 | 37.43% | $1.18B | |
$61,783,526 | 37 | 18.57% | $1.25B | |
$150,196,329 | 28 | -8.09% | $1.23B | |
Capricor Therapeutics, Inc. (CAPR) | $31,271,604 | 28 | 28.69% | $1.11B |
$121,322,364 | 24 | -6.74% | $1.25B | |
$49,930,821 | 19 | 34.14% | $1.1B | |
$21,945,105 | 15 | -26.51% | $1.09B | |
$26,254,270 | 14 | 24.18% | $1.01B | |
$48,220,484 | 14 | 2.13% | $1.05B | |
$103,194,328 | 13 | 9.02% | $1.04B | |
$49,967,154 | 11 | 62.08% | $1.19B | |
$5,794,001 | 10 | 23.26% | $1.08B | |
$117,959,652 | 9 | -12.47% | $1.19B | |
$21,792,890 | 6 | 75.72% | $1.05B | |
$40,959,889 | 5 | -1.88% | $996.61M | |
$19,420,853 | 5 | 4.35% | $1.18B | |
$18,704,399 | 5 | -20.93% | $1.22B | |
$45,070 | 4 | 10.31% | $1.13B | |
$33,624,000 | 2 | -50.37% | $917.6M |
| Increased Positions | 57 | +37.5% | 3M | +24.48% |
| Decreased Positions | 67 | -44.08% | 3M | -19.63% |
| New Positions | 33 | New | 2M | New |
| Sold Out Positions | 30 | Sold Out | 812,154 | Sold Out |
| Total Postitions | 142 | -6.58% | 14M | +4.84% |
| Blackrock, Inc. | $81,255.00 | 5.32% | 2.87M | -113,891 | -3.82% | 2025-09-30 |
| Vanguard Group Inc | $62,472.00 | 4.09% | 2.21M | -98,359 | -4.27% | 2025-09-30 |
| Geode Capital Management, Llc | $27,222.00 | 1.78% | 961,566 | -1,514 | -0.16% | 2025-09-30 |
| State Street Corp | $22,686.00 | 1.48% | 801,344 | -665,341 | -45.36% | 2025-09-30 |
| Morgan Stanley | $15,618.00 | 1.02% | 551,694 | +1,113 | +0.2% | 2025-09-30 |
| Pier Capital, Llc | $14,057.00 | 0.92% | 496,554 | +128,837 | +35.04% | 2025-09-30 |
| J. Goldman & Co Lp | $13,645.00 | 0.89% | 481,981 | +481,981 | New | 2025-09-30 |
| Dg Capital Management, Llc | $13,315.00 | 0.87% | 470,333 | +470,333 | New | 2025-09-30 |
| National Bank Of Canada /Fi/ | $11,259.00 | 0.74% | 397,700 | +229,000 | +135.74% | 2025-09-30 |
| Two Sigma Investments, Lp | $10,073.00 | 0.66% | 355,796 | +199,959 | +128.31% | 2025-09-30 |